Peptide Knowledge Base · Metabolic

Orforglipron: what it is, what the evidence says, and its real status

Not a peptide, a small molecule taken as a daily pill that activates the GLP-1 receptor. The convenience story of the category.

Can you actually get it?

Plain-English verdict: No availability record.

Regulatory status: No regulatory record.

How does Orforglipron work?

A non-peptide small molecule that activates the GLP-1 receptor, enabling once-daily oral dosing without injection.

What it does — and what it does not do

What it does: Studied for weight and glycemic control as an oral, injection-free GLP-1 option.

What it does not do: It is not a peptide, not approved, and not available; we tag it adjacent and capture the query.

How honest is the evidence?

Evidence grade B — Good human evidence.

Phase-2 data; Phase-3 ongoing, re-verify

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Long-term efficacy versus injectable agonists and full safety are still being established.

WADA status: Not prohibited.

How it is taken

What the literature reports: oral, once daily. Educational only, no dose figures.

Who should not take it

Investigational, safety not fully characterized; clinician-gated.

Sources

Orforglipron Phase-2 (NEJM 2023) · Phase-3 program (ongoing, re-verify)

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 18, 2026 · Peptós.LIFE · Not medical advice.